Clinical context
Cataract surgery outcomes are not defined by best-corrected visual acuity alone. Refractive accuracy, vision at different distances, spectacle dependence, contrast sensitivity, dysphotopsia and procedural safety all matter. Corneal and macular status, capsular support, cataract density and IOL calculation also shape the final result. A statistically convincing average therefore still has to be interpreted against the characteristics of an individual eye.
What was studied
This multicenter retrospective series compared Moussa with Kane, EVO, PEARL-DGS, K6, Hoffer-QST and Barrett Universal II. It included one eye from 2,550 patients after uncomplicated phacoemulsification at three UK centers. Biometry used IOLMaster 700, Lenstar LS900 or Pentacam AXL Wave. Constants were optimized to zero mean prediction error for each formula, lens and biometer combination. The primary outcome was mean absolute error, evaluated by bootstrap with 2,000 iterations and Holm correction.
How the evidence was produced
A cohort study describes how outcomes are associated with an exposure or treatment in an observed clinical population. This design is useful for routine practice, uncommon events and longer follow-up, but it remains vulnerable to confounding by indication, baseline risk differences and missing data. An association should not automatically be interpreted as a causal effect.
How to interpret the result
Moussa was competitive across several platforms, but statistical leadership was not a large clinical gain: margins were 0.011 D over Kane and 0.015 D over EVO, below ordinary IOL power increments. Similar ±0.50 D rates further limit the advantage. Moussa may serve as a cross-check, especially at axial-length extremes, rather than a proven replacement.
The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.
Clinical applicability
This evidence is most useful as a basis for preoperative discussion and surgical planning. It helps identify which outcomes should be measured and which trade-offs should be explained to patients. The average effect should not be generalized to every IOL, technique or patient without checking eligibility criteria, surgeon experience, biometry, ocular comorbidity and duration of follow-up.
Limitations
The study was retrospective, nonrandomized and restricted to uncomplicated surgery. Dataset-specific constant optimization may overestimate transportability to other centers and lenses. The abstract does not show device-lens error distributions, missing data or independent external validation. Check refraction timing, outlier handling, subgroup sizes, confidence intervals, formula provenance, calculator availability, funding and conflicts.
Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.
What to verify in the source
In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.